

# Jennifer L Sherr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2060463/publications.pdf>

Version: 2024-02-01

75  
papers

3,477  
citations

126907

33  
h-index

144013

57  
g-index

76  
all docs

76  
docs citations

76  
times ranked

2726  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.   | 2.2  | 69        |
| 2  | Incident diabetes complications among women with type 1 diabetes based on parity. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 4629-4634.  | 1.5  | 1         |
| 3  | Continuous Ketone Monitoring Consensus Report 2021. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 689-715.   | 2.2  | 18        |
| 4  | Safety and Glycemic Outcomes During the MiniMed <sup>®</sup> , <sup>®</sup> Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 178-189.                                | 4.4  | 107       |
| 5  | Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. <i>Clinical Diabetes</i> , 2022, 40, 168-184.   | 2.2  | 10        |
| 6  | Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (<scp>VibRate</scp>): A multinational prospective observational <scp>realâ€world</scp> cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 564-569.      | 4.4  | 12        |
| 7  | Diabetes Technology Meeting 2021. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210902.   | 2.2  | 2         |
| 8  | Pharmacodynamics, pharmacokinetics, safety, and tolerability of a readyâ€toâ€use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes. <i>Pediatric Diabetes</i> , 2022, 23, 754-762.                                | 2.9  | 0         |
| 9  | Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. <i>Diabetes Care</i> , 2022, 45, 1907-1910.   | 8.6  | 28        |
| 10 | How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod <sup>®</sup> 5 System. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 109998. | 2.8  | 15        |
| 11 | Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 593-599.  | 2.2  | 19        |
| 12 | A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. <i>Endocrine Practice</i> , 2021, 27, 545-551.  | 2.1  | 5         |
| 13 | American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. <i>Endocrine Practice</i> , 2021, 27, 505-537.   | 2.1  | 135       |
| 14 | Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1630-1640.  | 8.6  | 133       |
| 15 | Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. <i>Science</i> , 2021, 373, 522-527.   | 12.6 | 43        |
| 16 | Diabetes Technology Meeting 2020. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 916-960.   | 2.2  | 1         |
| 17 | Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents. <i>Pediatrics</i> , 2021, 148, .  | 2.1  | 8         |
| 18 | Adjunctive Therapies for Type 1 Diabetes. <i>Contemporary Endocrinology</i> , 2021, , 143-150.   | 0.1  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 174-184. | 4.4  | 61        |
| 20 | Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. <i>Diabetes Care</i> , 2020, 43, e1-e2.  | 8.6  | 59        |
| 21 | Changes in Device Uptake and Glycemic Control among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. <i>Journal of Diabetes Science and Technology</i> , 2020, 15, 193229682097212.                                  | 2.2  | 8         |
| 22 | Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. <i>Nature Medicine</i> , 2020, 26, 1380-1384.   | 30.7 | 127       |
| 23 | Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2388.                                       | 7.4  | 238       |
| 24 | Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. <i>Diabetes Therapy</i> , 2020, 11, 1591-1603.             | 2.5  | 21        |
| 25 | The dawn of automated insulin delivery: from promise to product. , 2020, , 327-356.  |      | 0         |
| 26 | Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2032-e2038.           | 3.6  | 26        |
| 27 | High residual C-peptide likely contributes to glycemic control in type 1 diabetes. <i>Journal of Clinical Investigation</i> , 2020, 130, 1850-1862.  | 8.2  | 73        |
| 28 | Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4356-4364.   | 3.6  | 118       |
| 29 | Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 101-104.  | 4.4  | 3         |
| 30 | Pharmacologic treatment options for type 1 diabetes: what's new?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 471-479.   | 3.1  | 13        |
| 31 | Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes. <i>Diabetes Care</i> , 2019, 42, 345-348.  | 8.6  | 36        |
| 32 | A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. <i>Pediatric Annals</i> , 2019, 48, e311-e318.  | 0.8  | 4         |
| 33 | Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670C System. <i>Diabetes Care</i> , 2018, 41, 789-796.  | 8.6  | 101       |
| 34 | Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1088-1094.  | 3.6  | 19        |
| 35 | Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings. <i>Pediatric Diabetes</i> , 2018, 19, 92-97.   | 2.9  | 42        |
| 36 | The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. <i>Pediatric Diabetes</i> , 2018, 19, 14-17.   | 2.9  | 23        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Enlarging the loop: closed-loop insulin delivery for type 1 diabetes. <i>Lancet, The</i> , 2018, 392, 1282-1284.   | 13.7 | 1         |
| 38 | Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. <i>Pediatric Diabetes</i> , 2018, 19, 1271-1275.   | 2.9  | 186       |
| 39 | Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults. <i>Diabetes Care</i> , 2018, 41, 1572-1578.   | 8.6  | 18        |
| 40 | ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. <i>Pediatric Diabetes</i> , 2018, 19, 302-325.   | 2.9  | 170       |
| 41 | Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 576-584.  | 4.4  | 22        |
| 42 | Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 961-965.   | 2.3  | 35        |
| 43 | Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. <i>Pediatric Diabetes</i> , 2017, 18, 348-355.                             | 2.9  | 46        |
| 44 | Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2994-3001.  | 3.6  | 38        |
| 45 | Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 618-622.  | 4.4  | 24        |
| 46 | Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1113-1131.   | 5.0  | 4         |
| 47 | Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. <i>Diabetes Care</i> , 2016, 39, 264-270.   | 8.6  | 86        |
| 48 | Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 794-799.  | 4.4  | 32        |
| 49 | Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. <i>Diabetes Care</i> , 2016, 39, 1127-1134.  | 8.6  | 75        |
| 50 | Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. <i>Diabetes Care</i> 2016;39:264-270. <i>Diabetes Care</i> , 2016, 39, e193-e194. | 8.6  | 13        |
| 51 | No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year. <i>Diabetes Care</i> , 2016, 39, e214-e215.   | 8.6  | 9         |
| 52 | Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 555-562.  | 8.6  | 91        |
| 53 | Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. <i>Diabetologia</i> , 2016, 59, 87-91.                                  | 6.3  | 203       |
| 54 | Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. <i>Diabetes Care</i> , 2014, 37, 773-779.   | 8.6  | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 20-25.   | 4.4 | 27        |
| 56 | Evolution of Abnormal Plasma Glucagon Responses to Mixed-Meal Feedings in Youth With Type 1 Diabetes During the First 2 Years After Diagnosis. <i>Diabetes Care</i> , 2014, 37, 1741-1744.                        | 8.6 | 38        |
| 57 | Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. <i>Pediatric Diabetes</i> , 2014, 15, 127-134.                           | 2.9 | 49        |
| 58 | Characterization of residual $\beta$ cell function in long-standing type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 154-162.   | 4.0 | 20        |
| 59 | Skin and Adhesive Issues With Continuous Glucose Monitors. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 745-751.  | 2.2 | 57        |
| 60 | Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges. <i>Diabetes Care</i> , 2014, 37, 210-216.                     | 8.6 | 56        |
| 61 | Insulin pumps in children with T1DM—we told you so. <i>Nature Reviews Endocrinology</i> , 2013, 9, 629-630.   | 9.6 | 0         |
| 62 | Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 1470-1476.                        | 8.6 | 32        |
| 63 | Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2909-2914.  | 8.6 | 105       |
| 64 | Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1123-1130.   | 2.2 | 85        |
| 65 | The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. <i>Diabetes Care</i> , 2012, 35, 690-692.  | 8.6 | 33        |
| 66 | Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. <i>Pediatric Diabetes</i> , 2012, 14, n/a-n/a.   | 2.9 | 19        |
| 67 | Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual $\beta$ -Cell Function. <i>Diabetes Care</i> , 2012, 35, 817-820. | 8.6 | 22        |
| 68 | Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas. <i>Expert Review of Medical Devices</i> , 2012, 9, 315-317.                              | 2.8 | 5         |
| 69 | Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1994-1999.                                | 8.6 | 124       |
| 70 | Diabetes Types 1 and 2 in the Pediatric Population. <i>Pediatric Annals</i> , 2012, 41, e1-7.   | 0.8 | 0         |
| 71 | A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. <i>Endocrine Practice</i> , 2011, 17, 862-866.               | 2.1 | 6         |
| 72 | New-generation diabetes management: glucose sensor-augmented insulin pump therapy. <i>Expert Review of Medical Devices</i> , 2011, 8, 449-458.  | 2.8 | 45        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today, 2009, 14, 973-981.                 | 6.4 | 10        |
| 74 | Past, present, and future of insulin pump therapy: better shot at diabetes control. Mount Sinai Journal of Medicine, 2008, 75, 352-361. | 1.9 | 37        |
| 75 | Prevention of type 1 diabetes: the time has come. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 334-343.              | 2.8 | 41        |